Diagnostic value of dual-tracer PET/CT with [18F]FDG and PSMA ligands in prostate cancer: an updated systematic review

Background Prostate-specific membrane antigen (PSMA) ligand PET/CT has significantly improved prostate cancer (PCa) imaging. However, in patients with poorly differentiated PCa or neuroendocrine transdifferentiation, [18F]fluorodeoxyglucose ([18F]FDG) PET/CT may provide additional diagnostic information. This systematic review evaluates the diagnostic value of combining [18F]FDG PET/CT with PSMA ligand PET/CT in PCa patients. Methods A systematic literature search of studies assessing the added diagnostic value of dual-tracer [18F]FDG and PSMA ligands PET/CT in PCa patients was conducted using PubMed/MEDLINE and Cochrane Library databases and available information was summarized. Results Fourteen studies (n = 901 patients) met the inclusion criteria. The dual-tracer approach identified [18F]FDG-positive/PSMA-negative (FDG+/PSMA−) lesions in a subset of patients, particularly those with Gleason Score (GS) ≥ 9. However, in patients with GS < 8, [18F]FDG PET/CT did not significantly improve lesion detection over PSMA ligand PET/CT alone. The presence of FDG+/PSMA− lesions correlated with aggressive tumor biology, increased risk of metastases, and worse prognosis. Conclusion Literature data showed that [18F]FDG PET/CT may serve as a valuable complementary imaging modality for high risk PCa patients potentially influencing staging and treatment decisions. Future prospective studies are warranted to further elucidate the prognostic significance and cost-effectiveness of combining [18F]FDG PET/CT with PSMA ligand PET/CT in PCa patients.

• Publication year

  2025

• Venue

  Frontiers in Medicine

• Publication date

  2025-07-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.3389/fmed.2025.1607227PMID 40703299PMCID 12283616
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognostic value of [18F]FDG- and PSMA-PET in patients evaluated for [177Lu]Lu-PSMA therapy of mCRPC

  2025cited by this paper
• Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects during 177Lu/225Ac treatment in neuroendocrine tumors and metastatic prostate cancer

  2025cited by this paper
• [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.

  2024cited by this paper
• Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [68Ga]Ga-/[18F]F-PSMA-11/-1007, [68Ga]Ga-FAPI-46 and 2-[18F]FDG PET/CT: a pilot study

  2024cited by this paper
• The Homunculus of unspecific bone uptakes associated with PSMA-targeted tracers: a systematic review-based definition

  2024cited by this paper
• Combination of [18F]FDG and [18F]PSMA-1007 PET/CT predicts tumour aggressiveness at staging and biochemical failure postoperatively in patients with prostate cancer

  2024cited by this paper
• Nomogram to predict the presence of PSMA-negative but FDG-positive lesion in castration-resistant prostate cancer: a multicenter cohort study

  2024cited by this paper
• Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study

  2024cited by this paper
• Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study.

  2024cited by this paper
• Interlesional response heterogeneity is associated with the prognosis of abiraterone treatment in metastatic castration-resistant prostate cancer.

  2024cited by this paper
• PET/CT and Conventional Imaging for the Assessment of Neuroendocrine Prostate Cancer: A Systematic Review

  2023cited by this paper
• 18F-FDG PET Is Not Inferior to 68Ga-PSMA PET for Detecting Biochemical Recurrent Prostate Cancer with a High Gleason Score: A Head-to-Head Comparison Study

  2023cited by this paper
• PSMA Radioligand Therapy in Prostate Cancer

  2023cited by this paper
• European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer.

  2023cited by this paper
• Meta-analysis of 18 F-PSMA-1007 PET/CT, 18 F-FDG PET/CT, and 68Ga-PSMA PET/CT in diagnostic efficacy of prostate Cancer

  2023cited by this paper
• Stereotactic Radiotherapy for Lesions Detected via 68Ga-Prostate-specific Membrane Antigen and 18F-Fluorodexyglucose Positron Emission Tomography/Computed Tomography in Patients with Nonmetastatic Prostate Cancer with Early Prostate-specific Antigen Progression on Androgen Deprivation Therapy: A Pro

  2022cited by this paper
• Flare on [18F]PSMA-1007 PET/CT after short-term androgen deprivation therapy and its correlation to FDG uptake: possible marker of tumor aggressiveness in treatment-naïve metastatic prostate cancer patients

  2022cited by this paper
• A Method Noise-Based Convolutional Neural Network Technique for CT Image Denoising

  2022cited by this paper
• The Added Value of 18F-FDG PET/CT Compared with 68Ga-PSMA PET/CT in Patients with Castration-Resistant Prostate Cancer

  2022cited by this paper
• The Heterogeneous Metabolic Patterns of Ganglia in 68Ga-PSMA, 11C-choline, and 18F-FDG PET/CT in Prostate Cancer Patients

  2021cited by this paper
• Prostate-specific Membrane Antigen-based Imaging of Castration-resistant Prostate Cancer.

  2021cited by this paper
• Intra-Individual Comparison of 18F-PSMA-1007 and 18F-FDG PET/CT in the Evaluation of Patients With Prostate Cancer

  2021cited by this paper
• Diagnostic value of 18F-FDG PET/CT in patients with biochemical recurrent prostate cancer and negative 68Ga-PSMA PET/CT

  2021cited by this paper
• Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

  2021cited by this paper
• [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.

  2021cited by this paper
• Use of 68Ga-PSMA-11 and 18F-FDG PET-CT Dual-Tracer to Differentiate Between Lymph Node Metastases and Ganglia

  2021cited by this paper
• Dual-Tracer Positron-Emission Tomography Using Prostate-Specific Membrane Antigen and Fluorodeoxyglucose for Staging of Prostate Cancer: A Systematic Review

  2021cited by this paper
• A Comparison of 18F-DCFPyL, 18F-NaF, and 18F-FDG PET/CT in a Prospective Cohort of Men with Metastatic Prostate Cancer

  2021cited by this paper
• Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.

  2020cited by this paper
• Characterization of Models for Identifying Physical and Cognitive Frailty in Older Adults With Diabetes: Systematic Review and Meta-Analysis

  2020cited by this paper
• Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

  2020cited by this paper
• Detection Rate of Prostate-Specific Membrane Antigen Tracers for Positron Emission Tomography/Computed Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis.

  2020cited by this paper
• Diagnostic Performance of PET Imaging Using Different Radiopharmaceuticals in Prostate Cancer According to Published Meta-Analyses

  2020cited by this paper
• A Prospective Trial of 68Ga-PSMA and 18F-FDG PET/CT in Nonmetastatic Prostate Cancer Patients with an Early PSA Progression During Castration

  2020cited by this paper
• PSMA-Ligand PET for Early Castration-Resistant Prostate Cancer: A Retrospective Single-Center Study

  2020cited by this paper
• CT image denoising using multivariate model and its method noise thresholding in non-subsampled shearlet domain

  2020cited by this paper
• Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.

  2019cited by this paper
• Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.

  2018cited by this paper
• Systematic reviews and meta-analyses of diagnostic studies: a practical guideline

  2017cited by this paper
• 18F-fluorodeoxyglucose PET/CT for detection of disease in patients with prostate-specific antigen relapse following radical treatment of a local-stage prostate cancer.

  2016cited by this paper
• Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.

  2015cited by this paper
• Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations

  2013cited by this paper
• Dual Tracer 11C-Choline and FDG-PET in the Diagnosis of Biochemical Prostate Cancer Relapse After Radical Treatment

  2010cited by this paper

• Clinically oriented immune heterogeneity in prostate cancer: emerging targets and strategies.

  2026cites this paper
• Distinct prognostic value of [18F]FDG PET and [68Ga]Ga-PSMA-11 PET in advanced hormone-sensitive prostate cancer.

  2026cites this paper
• Added Value of Interim FDG PET/CT in Resolving PSA-PSMA Discordance during PSMA-targeted Radioligand Therapy.

  2025cites this paper